Foresight Diagnostics Inc.

Foresight Diagnostics was founded by four Stanford University physicians and scientists who sought to develop high-performing circulating tumor DNA (ctDNA) assays by improving the limits of detection through innovative techniques and enhanced bioinformatics. Our product, Foresight CLARITY™, utilizes a proprietary and patented phased variant (PV) detection method to improve the accuracy of ctDNA tests and minimal residual disease (MRD) measurement. Foresight Diagnostics was acquired by Natera in December 2025 and operates a CLIA laboratory in Boulder, Colorado.